These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 21343372)

  • 1. Inhibition of prostate cancer osteoblastic progression with VEGF121/rGel, a single agent targeting osteoblasts, osteoclasts, and tumor neovasculature.
    Mohamedali KA; Li ZG; Starbuck MW; Wan X; Yang J; Kim S; Zhang W; Rosenblum MG; Navone NM
    Clin Cancer Res; 2011 Apr; 17(8):2328-38. PubMed ID: 21343372
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of prostate tumor growth and bone remodeling by the vascular targeting agent VEGF121/rGel.
    Mohamedali KA; Poblenz AT; Sikes CR; Navone NM; Thorpe PE; Darnay BG; Rosenblum MG
    Cancer Res; 2006 Nov; 66(22):10919-28. PubMed ID: 17108129
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cytotoxicity of VEGF(121)/rGel on vascular endothelial cells resulting in inhibition of angiogenesis is mediated via VEGFR-2.
    Mohamedali KA; Ran S; Gomez-Manzano C; Ramdas L; Xu J; Kim S; Cheung LH; Hittelman WN; Zhang W; Waltenberger J; Thorpe PE; Rosenblum MG
    BMC Cancer; 2011 Aug; 11():358. PubMed ID: 21849059
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dual targeting c-met and VEGFR2 in osteoblasts suppresses growth and osteolysis of prostate cancer bone metastasis.
    Lee C; Whang YM; Campbell P; Mulcrone PL; Elefteriou F; Cho SW; Park SI
    Cancer Lett; 2018 Feb; 414():205-213. PubMed ID: 29174801
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multimodality molecular imaging of glioblastoma growth inhibition with vasculature-targeting fusion toxin VEGF121/rGel.
    Hsu AR; Cai W; Veeravagu A; Mohamedali KA; Chen K; Kim S; Vogel H; Hou LC; Tse V; Rosenblum MG; Chen X
    J Nucl Med; 2007 Mar; 48(3):445-54. PubMed ID: 17332623
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pristimerin Inhibits Prostate Cancer Bone Metastasis by Targeting PC-3 Stem Cell Characteristics and VEGF-Induced Vasculogenesis of BM-EPCs.
    Huang S; He P; Peng X; Li J; Xu D; Tang Y
    Cell Physiol Biochem; 2015; 37(1):253-68. PubMed ID: 26302893
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of transforming growth factor beta (TGF-β) receptor I kinase inhibitor on prostate cancer bone growth.
    Wan X; Li ZG; Yingling JM; Yang J; Starbuck MW; Ravoori MK; Kundra V; Vazquez E; Navone NM
    Bone; 2012 Mar; 50(3):695-703. PubMed ID: 22173053
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The vascular-ablative agent VEGF(121)/rGel inhibits pulmonary metastases of MDA-MB-231 breast tumors.
    Ran S; Mohamedali KA; Luster TA; Thorpe PE; Rosenblum MG
    Neoplasia; 2005 May; 7(5):486-96. PubMed ID: 15967101
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Light-enhanced VEGF
    Weyergang A; Fremstedal AS; Skarpen E; Peng Q; Mohamedali KA; Eng MS; Cheung LH; Rosenblum MG; Waltenberger J; Berg K
    J Control Release; 2018 Oct; 288():161-172. PubMed ID: 30217739
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The vascular-targeting fusion toxin VEGF121/rGel inhibits the growth of orthotopic human bladder carcinoma tumors.
    Mohamedali KA; Kedar D; Sweeney P; Kamat A; Davis DW; Eve BY; Huang S; Thorpe PE; Dinney CP; Rosenblum MG
    Neoplasia; 2005 Oct; 7(10):912-20. PubMed ID: 16242074
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BMP4 promotes prostate tumor growth in bone through osteogenesis.
    Lee YC; Cheng CJ; Bilen MA; Lu JF; Satcher RL; Yu-Lee LY; Gallick GE; Maity SN; Lin SH
    Cancer Res; 2011 Aug; 71(15):5194-203. PubMed ID: 21670081
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Photochemical internalization augments tumor vascular cytotoxicity and specificity of VEGF(121)/rGel fusion toxin.
    Weyergang A; Cheung LH; Rosenblum MG; Mohamedali KA; Peng Q; Waltenberger J; Berg K
    J Control Release; 2014 Apr; 180():1-9. PubMed ID: 24531010
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacological Inhibition of NFκB Reduces Prostate Cancer Related Osteoclastogenesis In Vitro and Osteolysis Ex Vivo.
    Marino S; Bishop RT; Carrasco G; Logan JG; Li B; Idris AI
    Calcif Tissue Int; 2019 Aug; 105(2):193-204. PubMed ID: 30929064
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Specific targeting of tumor endothelial cells by a shiga-like toxin-vascular endothelial growth factor fusion protein as a novel treatment strategy for pancreatic cancer.
    Hotz B; Backer MV; Backer JM; Buhr HJ; Hotz HG
    Neoplasia; 2010 Oct; 12(10):797-806. PubMed ID: 20927318
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prostate cancer cells-osteoblast interaction shifts expression of growth/survival-related genes in prostate cancer and reduces expression of osteoprotegerin in osteoblasts.
    Fizazi K; Yang J; Peleg S; Sikes CR; Kreimann EL; Daliani D; Olive M; Raymond KA; Janus TJ; Logothetis CJ; Karsenty G; Navone NM
    Clin Cancer Res; 2003 Jul; 9(7):2587-97. PubMed ID: 12855635
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro and in vivo studies of a VEGF121/rGelonin chimeric fusion toxin targeting the neovasculature of solid tumors.
    Veenendaal LM; Jin H; Ran S; Cheung L; Navone N; Marks JW; Waltenberger J; Thorpe P; Rosenblum MG
    Proc Natl Acad Sci U S A; 2002 Jun; 99(12):7866-71. PubMed ID: 12060733
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Skeletal Colonization by Breast Cancer Cells Is Stimulated by an Osteoblast and β2AR-Dependent Neo-Angiogenic Switch.
    Mulcrone PL; Campbell JP; Clément-Demange L; Anbinder AL; Merkel AR; Brekken RA; Sterling JA; Elefteriou F
    J Bone Miner Res; 2017 Jul; 32(7):1442-1454. PubMed ID: 28300321
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Stage-specific characterization of the vascular endothelial growth factor axis in prostate cancer: expression of lymphangiogenic markers is associated with advanced-stage disease.
    Kaushal V; Mukunyadzi P; Dennis RA; Siegel ER; Johnson DE; Kohli M
    Clin Cancer Res; 2005 Jan; 11(2 Pt 1):584-93. PubMed ID: 15701844
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 16.